

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 15 January 2001 (15.01.01)	
<b>International application No.</b> PCT/GB00/01813	<b>Applicant's or agent's file reference</b> 8.41.69960/001
<b>International filing date</b> (day/month/year) 11 May 2000 (11.05.00)	<b>Priority date</b> (day/month/year) 11 May 1999 (11.05.99)
<b>Applicant</b> HESSE, Robert, Henry et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 08 December 2000 (08.12.00)

☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b> Juan Cruz Telephone No.: (41-22) 338.83.38
--	--

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/01813

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J9/00 C07J41/00 A61K31/575 C07J51/00 A61P17/02  
A61P19/08 A61P37/06 A61P29/00 A61P35/00 A61P21/00  
A61P9/10 A61P5/20 A61P17/00 A61P9/12 A61P19/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 131, no. 8, 23 August 1999 (1999-08-23) Columbus, Ohio, US; abstract no. 97731, MOUNTFORD, JOANNE C. ET AL: "Estrone potentiates myeloid cell differentiation: a role for 17.beta.-hydroxysteroid dehydrogenase in modulating hemopoiesis" XP002147254 abstract & EXP. HEMATOL. (N. Y.) (1999), 27(3), 451-460  --	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

18 September 2000

Date of mailing of the international search report

28/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl  
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

# INTERNATIONAL SEARCH REPORT

In .ational Application No

PCT/GB 00/01813

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P11/06 A61P25/28 A61P15/18 A61P7/02 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 120, no. 23, 6 June 1994 (1994-06-06) Columbus, Ohio, US; abstract no. 290344, LAJEUNESSE, DANIEL: "Effect of 17.beta.-estradiol on the human osteosarcoma cell line MG-63" XP002147255 abstract & BONE MINER. (1994), 24(1), 1-16 , -/-	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

18 September 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5018 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 240-2040, Tx. 31 651 epo NL  
Fax: (+31-70) 240-2016

Authorized officer

Watchorn, P

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No.  
PCT/GB 00/01813

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 119, no. 7, 16 August 1993 (1993-08-16) Columbus, Ohio, US; abstract no. 63468, ESCALEIRA, MARIA TERESA F. ET AL: "Sex steroids induced up-regulation of 1,25-dihydroxyvitamin D3 receptors in T 47D breast cancer cells" XP002147256 abstract & J. STEROID BIOCHEM. MOL. BIOL. (1993), 45(4), 257-63 ,	1-21
A	CHEMICAL ABSTRACTS, vol. 116, no. 25, 22 June 1992 (1992-06-22) Columbus, Ohio, US; abstract no. 248829, LIEL, YAIR ET AL: "Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8)" XP002147257 abstract & ENDOCRINOLOGY (BALTIMORE) (1992), 130(5), 2597-601 ,	1-21
A	US 3 562 260 A (RUGGIERI PIETRO DE ET AL) 9 February 1971 (1971-02-09) column 2, line 8 - line 26; examples 3,4,6,11,21	1-21
A	US 3 717 627 A (LAING S ET AL) 20 February 1973 (1973-02-20) column 1, paragraph 2; example 4	1-21

# INTERNATIONAL SEARCH REPORT

Information on patent family members


International Application No

PCT/GB 00/01813

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3562260	A	09-02-1971	US 3494918 A	10-02-1970
US 3717627	A	20-02-1973	CH 568335 A	31-10-1975
			DE 1926574 A	24-09-1970
			DK 125200 B	15-01-1973
			FR 2009257 A	30-01-1970
			GB 1267915 A	22-03-1972
			JP 50011911 B	07-05-1975
			NL 6907883 A	26-11-1969

Claims:

1. Compounds of formula (I)



in which:

15  $R^1$  and  $R^2$ , which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group;

$R^3$  represents a methyl group having  $\alpha$ - or  $\beta$ -configuration;

20  $R^4$  represents a hydrogen atom or an etherifying or esterifying group;

$R^5$  represents a hydrogen atom, a hydroxyl group or a lower alkoxy group;

25 X represents a group  $OR^4$ , wherein  $R^4$  is as defined above, or a group  $NR^6R^7$  wherein  $R^6$  represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and  $R^7$  is a hydrogen atom or a lower alkyl group;

30 Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and

35 the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position.

2. Compounds of formula (I) as claimed in claim 1

wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from C<sub>1-6</sub> alkyl groups and C<sub>2-7</sub> alkenyl and alkynyl groups.

3. Compounds of formula (I) as claimed in claim 2  
5 wherein R<sup>1</sup> and R<sup>2</sup> are straight chain groups.

4. Compounds of formula (I) as claimed in claim 2  
10 wherein R<sup>1</sup> and R<sup>2</sup> are selected from methyl, ethyl and propargyl groups.

5. Compounds of formula (I) as claimed in any of the  
preceding claims wherein R<sup>4</sup> a hydrogen atom, a silyl  
group, a C<sub>1-6</sub> alkyl group optionally interrupted by one  
or more oxygen atoms or substituted by a lower  
15 cycloalkyl group, a cyclic ether group, a C<sub>1-6</sub> alkanoyl  
group, an aroyl group, a C<sub>1-6</sub> alkane sulphonyl or  
halogenated methane sulphonyl group, or an arene  
sulphonyl group.

6. Compounds of formula (I) as claimed in claim 5  
20 wherein R<sup>4</sup> is a hydrogen atom.

7. Compounds of formula (I) as claimed in claim 5  
25 wherein R<sup>4</sup> is a metabolically labile group or a lower  
alkyl group.

8. Compounds of formula (I) as claimed in any of the  
preceding claims wherein R<sup>5</sup> represents a hydrogen atom or  
a methoxy group.

9. Compounds of formula (I) as claimed in any of the  
preceding claims wherein X represents a hydroxyl group  
or a group of formula NR<sup>6</sup>R<sup>7</sup> wherein:

35 R<sup>6</sup> is a C<sub>1-6</sub> alkyl group, C<sub>6-12</sub> carbocyclic aryl C<sub>1-6</sub>  
alkyl group, C<sub>1-6</sub> alkanoyl group, C<sub>6-12</sub> carbocyclic aryl  
C<sub>2-6</sub> alkanoyl group, C<sub>7-13</sub> carbocyclic aroyl group or any  
of the preceding groups substituted by one or more halo,



C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkanoyl, C<sub>1-4</sub> alkylamino, di(C<sub>1-4</sub> alkyl)amino, nitro, carbamoyl or C<sub>1-4</sub> alkanoylamino substituents; and

R<sup>7</sup> is a hydrogen atom or a C<sub>1-6</sub> alkyl group.

5

10. Compounds of formula (I) as claimed in claim 9 wherein X represents a hydroxyl, amino, methylamino, ethylamino, N-ethyl-N-methylamino, acetylamino, benzamido or phenylacetylamino group.

10

11. Compounds of formula (I) as claimed in any of the preceding claims wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

15

12. Compounds of formula (I) as claimed in claim 11 wherein Y is a straight chain C<sub>2-6</sub> group.

20

13. Compounds of formula (I) as claimed in any of the preceding claims wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned  $\alpha$ -,  $\beta$ - or  $\gamma$ - to the group -C(R<sup>1</sup>)(R<sup>2</sup>)-X or  $\alpha$ - to any triple bond present in the group Y.

25

14. Compounds as claimed in claim 11 wherein Y is selected from ethylene, trimethylene, tetramethylene, vinylene, buta-1,3-dienylene, prop-2-ynylene and 1-hydroxyprop-2-ynylene.

30

15. Compounds of formula (I) as claimed in claim 1 wherein:

R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, each represents a lower alkyl group;

R<sup>5</sup> represents a hydrogen atom; and

X represents a group NR<sup>6</sup>R<sup>7</sup> wherein R<sup>7</sup> is hydrogen.

35

16. The compounds:

- 25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
5 25-ethylamino-3-hydroxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-methylamino-3-hydroxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-dimethylamino-3-hydroxy-24-homo-19-nor-cholest-  
10 1,3,5(10),16-tetraene;  
25-(N-ethyl-N-methylamino)-3-hydroxy-24-homo-19-  
nor-cholest-1,3,5(10),16-tetraene;  
25-acetylamino-3-methoxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
15 25-acetylamino-3-ethoxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-acetylamino-3-isobutoxy-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-benzamido-3-hydroxy-24-homo-19-nor-cholest-  
20 1,3,5(10),16-tetraene;  
25-phenylacetylamino-3-hydroxy-24-homo-19-nor-  
cholest-1,3,5(10),16-tetraene;  
25-acetylamino-3-hydroxy-24-homo-19-nor-cholest-  
1,3,5(10)-triene;  
25 3,24-dihydroxy-24-propargyl-19-26,27-trisnor-  
cholest-1,3,5(10)-triene;  
2-methoxy-3,24-dihydroxy-24-propargyl-19,26,27-  
trisnor-cholesta-1,3,5(10)-triene;  
3,24-dihydroxy-20-epi-24-propargyl-19,26,27-  
30 trisnor-cholest-1,3,5(10)-triene;  
3,24-dihydroxy-24,24-bispropargyl-19-nor-chol-  
1,3,5(10),22-tetraene;  
2-methoxy-3,24-dihydroxy-24,24-bispropargyl-19-nor-  
chol-1,3,5(10),22-tetraene;  
35 3,24-dihydroxy-20-epi-24,24-bispropargyl-19-nor-  
chol-1,3,5(10),22-tetraene;  
3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-

1,3,5(10)-trien-23-yne;

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

5 3-hydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-triene;

2-methoxy-3-hydroxy-25-amino-26,27-bishomo-19-nor-cholesta-1,3,5(10)-triene;

10 3-hydroxy-20-epi-25-amino-26,26-bishomo-19-nor-cholesta-1,3,5(10)-triene;

3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

15 2-methoxy-3-hydroxy-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3-hydroxy-20-epi-25-acetylamino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

20 2-methoxy-3,22-dihydroxy-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

3,22-dihydroxy-20-epi-25-amino-26,27-bishomo-19-nor-cholest-1,3,5(10)-trien-23-yne;

25 2-methoxy-3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;

2-methoxy-3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;

2-methoxy-3-hydroxy-25-acetylamino-19-nor-cholest-1,3,5(10),16-tetraene;

30 2-methoxy-3-hydroxy-25-amino-19-nor-cholest-1,3,5(10),16-tetraene;

3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;

35 3-hydroxy-24-homo-25-amino-19-nor-cholest-1,3,5(10),6,8,16-hexaene;

3,25-dihydroxy-19-nor-cholest-1,3,5(10)-trien-23-yne;

- 67 -

- 3,25-dihydroxy-19-nor-cholest-1,3,5(10)-triene;  
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-  
trien-23-yne;  
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-  
5 trien-23-yne;  
2-methoxy-3,25-dihydroxy-19-nor-cholest-1,3,5(10)-  
triene;  
3,25-dihydroxy-20-epi-19-nor-cholest-1,3,5(10)-  
triene;  
10 3,25-dihydroxy-24,24a-bishomo-19-nor-cholest-  
1,3,5(10),22,24(24a)-pentaene;  
25-amino-3-hydroxy-20-epi-24-homo-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-  
15 cholest-1,3,5(10),16-tetraene;  
25-amino-3-hydroxy-20-epi-19-nor-cholest-  
1,3,5(10),16-tetraene;  
25-acetylamino-3-hydroxy-20-epi-24-homo-19-nor-  
cholest-1,3,5(10),16-tetraene;  
20 3-hydroxy-24-homo-25-acetylamino-19-nor-cholest-  
1,3,5(10),6,16-pentaene; and  
3-hydroxy-24-homo-25-amino-19-nor-cholest-  
1,3,5(10),6,16-pentaene.
- 25 17. Active compounds of formula (I) as claimed in any  
preceeding claim for use in management of neoplastic  
disease; as agents to promote wound healing; in burn  
management; in treatment of bone diseases, autoimmune  
30 inflammatory diseases, neoplasias or hyperplasias,  
myopathy, enteropathy or spondylitic heart disease; in  
suppression of parathyroid hormone; in treatment of  
dermatological diseases, hypertension, rheumatoid  
arthritis, psoriatic arthritis, secondary  
35 hyperparathyroidism, asthma, cognitive impairment or  
senile dementia; in fertility control in either human or  
animal subjects; in management of disorders involving

blood clotting; or in reduction of serum cholesterol.

18. The use of an active compound of formula (I) as claimed in any one of claims 1 to 16 for the manufacture  
5 of a medicament for use in management of neoplastic disease; as an agent to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias,  
10 myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or  
15 senile dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

19. Pharmaceutical compositions comprising an active  
20 compound of formula (I) as claimed in any one of claims 1 to 16 in admixture with one or more physiologically acceptable carriers or excipients.

20. A method of treatment of a human or animal subject  
25 in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic  
30 heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or  
35 senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a therapeutically effective amount of an

active compound of formula (I) as claimed in any of claims 1 to 16.

21. A process for the preparation of a compound of  
5 formula (I) as defined in claim 1 which comprises  
reacting a compound containing a precursor for the  
desired 17-position side chain in one or more stages and  
with one or more reactants serving to form the said  
desired 17-position side chain, followed if necessary  
10 and/or desired by removal of any O-protecting group.

# PATENT COOPERATION TREATY

# PCT

REC'D 20 FEB 2001

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 8.69960/001	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/01813	International filing date (day/month/year) 11/05/2000	Priority date (day/month/year) 11/05/1999
International Patent Classification (IPC) or national classification and IPC C07J9/00		
Applicant MARSDEN, John, Christopher et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  12/12/2000	Date of completion of this report  14.02.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Ladenburger, C  Telephone No. +49 89 2399 8276  

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01813

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

**Description, pages:**

1-61 as originally filed

**Claims, No.:**

1-21 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01813

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 20 as to IA.

because:

☒ the said international application, or the said claims Nos. 20 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-21
	No:	Claims	

Inventive step (IS)	Yes:	Claims	1-21
	No:	Claims	

Industrial applicability (IA)	Yes:	Claims	1-19,21
-------------------------------	------	--------	---------

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/01813

---

No: Claims

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

III. Non-establishment of opinion

Claim 20 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT).

V.2 Reasoned statement; Citations and explanations

1. Having regard to the fact that the prior art documents cited in the ISR neither disclose the compounds of claim 1 or very close analogs nor relate to compounds which possess the same spectrum of activities, the subject-matter of claims 1-21 can be recognised as novel and inventive vis-à-vis this state of the art. It is obviously industrially applicable (except claim 20).
2. For the assessment of claim 20 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

VIII. Certain observations

1. It is reminded that the breadth of the main claim should be such that it represents a reasonable generalisation over the examples provided, and such that every compound falling within its scope actually provides a solution to the problem underlying the invention.  
In the present case, having regard to the limited variety of the compounds effectively prepared and to the absence of any concrete test data in the description, it is questionable whether the scope of claims 1-21 is reasonable and justified. Especially the definitions of R<sup>4</sup>, R<sup>6</sup> and Y appear to be too broad and widely speculative.

Thus the Applicant should ensure that principal claim 1 covers only compounds which actually solve the given problem.

2. The relative term "lower" used in several claims has no well-recognised meaning and leaves a doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of these claims unclear. The number of carbon atoms should be specified according to the description.
3. Claim 16 comprises all the features of claim 1 and is therefore not appropriately formulated as a claim dependent on the latter (Rule 6.4 PCT).
4. The term "active" used in the expression "active compound(s) of formula (I)" in claims 17-20 should be deleted to avoid any ambiguity as to the scope of these claims. The question arise whether this term is intended to have a limiting function, and that not all compounds of formula (I) are actually active (see above VIII.1). If protection is also sought for intermediate compounds, such compounds should be clearly distinguished from the "active" compounds.